Difference between revisions of "Part:BBa K4165151"
 
(2 intermediate revisions by one other user not shown)
Line 3: Line 3:
 
<partinfo>BBa_K4165151 short</partinfo>
 
<partinfo>BBa_K4165151 short</partinfo>
  
−
Tau binding peptide targeting the PHF seed of Tau
+
A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.
  
 
===Usage and Biology===
 
===Usage and Biology===
  
−
M4W39 is a peptide with amino acid sequence of DVWMINKKWK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. M4W39 can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC<sub>50</sub> for inhibition of tau aggregates were 2.9 μM.
+
M4W39 is a peptide with amino acid sequence of DVWMINKKWK, it is acquired by mirror phage display to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. M4W39 can bind to PHF* in a mean that can disrupt the interaction between fibrils and consequently reduce the aggregates.
  
−
<!-- -->
+
<p style=" font-weight: bold; font-size:14px;"> IC<sub>50</sub> = 2.9 μM </p>
−
<span class='h3bb'>Sequence and Features</span>
+
 
 +
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 
<partinfo>BBa_K4165151 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165151 SequenceAndFeatures</partinfo>
  
Line 21: Line 22:
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/m4w39.png" style="margin-left:200px;" alt="" width="300" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/m4w39.png" style="margin-left:300px;" alt="" width="300" /></p>
 
</html>
 
</html>
  
Line 31: Line 32:
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/w4m39-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/w4m39-qa.png" style="margin-left:50px;" alt="" width="800" /></p>
 
</html>
 
</html>
  
  
 +
<!-- -->
 
===References===
 
===References===
 
1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.
 
1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.

Latest revision as of 14:31, 11 October 2022


M4W39 Peptide

A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.

Usage and Biology

M4W39 is a peptide with amino acid sequence of DVWMINKKWK, it is acquired by mirror phage display to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. M4W39 can bind to PHF* in a mean that can disrupt the interaction between fibrils and consequently reduce the aggregates.

IC50 = 2.9 μM

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

modeled by AlphaFold2, Apptest, ITASSER, best model obtained from AlphaFold2 


                            Figure 1.: Predicted 3D structure of Synthetic peptide M4W39.


Table 1: Quality assessment parameters of M4W39 model.


References

1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.